ÉϺ£Í¬Ö¾ - ÉϺ£Í¬Ö¾ÁÄÌìÊÒ - ÉϺ£Í¬Ö¾½»ÓÑ - Mollis Shanghai UniClub
|
¡¾½ËÕͬ־»áËù¡¿ÖйúÔ죡FDA½ñÈÕÅú×¼10ÄêÀ´Ê׿ÐÂHIVÁÆ·¨ ¡¡¡¡Ò©Ã÷¿µµÂ/±¨µÀ£º3ÔÂ7ÈÕ£¬ÃÀ¹úFDAÐû²¼Åú×¼ÖÐÔ£ÐÂÒ©(TaiMed Biologics)µÄTrogarzo (ibalizumab-uiyk)ÉÏÊУ¬×÷ΪһÖÖȫеĿ¹Äæ×ªÂ¼²¡¶¾ÁÆ·¨£¬ÖÎÁÆÏÖÓжàÖÖÁÆ·¨¾ùÎÞ·¨ÆðЧµÄ³ÉÈËHIV¸ÐȾÕß¡£ÖµµÃÒ»ÌáµÄÊÇ£¬ÕâÊÇÃÀ¹úFDAÔÚ2018ÄêÅú×¼µÄÊ׿ÐÂÉúÎïÒ©¡£ ¡¡¡¡TrogarzoÊÇÓÉÖÐÔ£ÐÂÒ©´´ÖÆ¡¢Ò©Ã÷ÉúÎïÐÖúÉú²úµÄ´´ÐÂÒ©Îï¡£ËüÒ²ÊÇÊ×ÀýÔÚÖйúÉú²ú¡¢²¢µÃµ½ÃÀ¹úFDAÅú×¼½øÈëÃÀ¹úÁÙ´²ÊÔÑéµÄÎÞ¾úÉúÎïÖÆ¼Á¡£×÷ΪһÖÖ¡°²¡¶¾ÇÖÈëÒÖÖÆ¼Á¡±£¬ibalizumabÄܹ»½áºÏTϸ°û±íÃæµÄHIVÖ÷ÒªÊÜÌåCD4£¬ÒÔ×èÖ¹ÕâЩϸ°ûÔâµ½²¡¶¾µÄÈëÇÖ¡£×÷Ϊ10¶àÄêÀ´Ê׿î¾ßÓÐÈ«ÐÂ×÷ÓûúÖÆµÄ¿¹Äæ×ªÂ¼²¡¶¾ÁÆ·¨£¬ibalizumabÔø»ñµÃÃÀ¹úFDA°ä·¢µÄÍ»ÆÆÐÔÁÆ·¨È϶¨¡¢ÓÅÏÈÉóÆÀ×ʸñ¡¢¿ìËÙͨµÀ×ʸñ¡¢ÒÔ¼°¹Â¶ùÒ©×ʸñ¡£ ¡¡¡¡Õâ¿îÐÂÒ©µÄ°²È«ÐÔÓëÁÆÐ§ÔÚÒ»ÏîÁÙ´²ÊÔÑéÖеõ½ÁËÑéÖ¤¡£¸ÃÊÔÑéÕÐļÁË40Ãû¸ÐȾÓжàÖØÄÍÒ©ÐÔHIVµÄ»¼Õߣ¬ËûÃǾùÖØ¶È¾ÖΣ¬ÓÐЩ»¼ÕßÉõÖÁÒѾ½ÓÊܹý10ÖÖ»ò¸ü¶àµÄ¿¹Äæ×ªÂ¼²¡¶¾ÁÆ·¨¡£È»¶ø¼´±ã½ÓÊÜÁË´óÁ¿ÖÎÁÆ£¬ËûÃÇѪҺÖеIJ¡¶¾Ë®Æ½(HIV-RNA)ÒÀ¾ÉºÜ¸ß¡£Ñо¿ÈËÔ±·¢ÏÖ£¬ÔÚÏÖÓеÄÁÆ·¨ÖжîÍâ¼ÓÈëTrogarzoµÄÖÎÁƺó£¬Ö»Òª¶Ì¶ÌÒ»ÖÜ£¬´ó²¿·Ö»¼ÕßѪҺÖеÄHIV-RNAˮƽ¾ÍÓÐÏÔÖøÏ½µ¡£24Öܺó£¬43%µÄ»¼Õ߯äHIV-RNAˮƽÒÀ¾ÉµÃµ½ÁËÒÖÖÆ¡£¶ÔÓÚÕâЩ¼±È±ÖÎÁÆ·½°¸µÄ»¼Õߣ¬Trogarzo´øÀ´ÁËÏÔÖøÒæ´¦¡£ ¡¡¡¡¡°¾¡¹Ü´ó²¿·Ö¸ÐȾHIVµÄ»¼ÕßÄÜÔÚ2ÖÖ»ò¶àÖÖ¿¹Äæ×ªÂ¼²¡¶¾ÁÆ·¨µÄ×éºÏÏ£¬µÃµ½ºÜºÃµÄÖÎÁÆ£¬µ«ÒÀ¾ÉÓÐС²¿·Ö»¼ÕßÔÚ´óÁ¿¿¹HIVÐÂÒ©µÄÖÎÁƺ󣬲úÉúÁ˶àÖØÄÍÒ©ÐÔ¡£ÕâÏÞÖÆÁËËûÃÇÄÜʹÓõÄÖÎÁÆ·½°¸£¬Ò²ÈÃËûÃÇÓиü¸ßµÄ·çÏÕ»¼ÉÏHIV¸ÐȾÏà¹ØµÄ²¢·¢Ö¢£¬µ¼ÖÂËÀÍö£¬¡±ÃÀ¹úFDAÒ©Æ·ÆÀ¹ÀºÍÑо¿ÖÐÐĵĿ¹²¡¶¾²úÆ·²¿¸±Ö÷ÈÎJeff Murray²©Ê¿ËµµÀ£¬¡°TrogarzoÊÇÒ»ÀàÐÂÐÍ¿¹Äæ×ªÂ¼²¡¶¾ÁÆ·¨ÀïµÄÊ׿îÐÂÒ©£¬ÄÜΪÄÇЩÎÞÒ©¿ÉÓõÄHIV¸ÐȾÕß´øÀ´ÏÔÖøµÄÒæ´¦¡£ÐÂÁÆ·¨ÓÐÍûÄܸÄÉÆËûÃǵÄÔ¤ºó¡£¡± ¡¡¡¡ÎÒÃÇ×£ºØÖÐÔ£ÐÂÒ©µÄÕâ¿îÐÂҩ˳ÀûÉÏÊУ¬Ò²ÆÚ´ýËüÄÜΪHIVÖØ¶È¸ÐȾÕß´øÀ´¸£Òô£¬ÓÐЧ¿ØÖÆËûÃǵIJ¡Çé¡£ ¡¡¡¡²Î¿¼×ÊÁÏ£º ¡¡¡¡¢Å FDA approves new HIV treatment for patients who have limited treatment options ¡¡¡¡¢Æ Theratechnologies Announces FDA Approval of Breakthrough Therapy, Trogarzo? (ibalizumab-uiyk) Injection, the First HIV-1 Inhibitor and Long-Acting Monoclonal Antibody for Multidrug Resistant HIV-1 ¡¡¡¡(À´Ô´£ºÒ©Ã÷¿µµÂ) |
Archiver|ÊÖ»ú°æ|СºÚÎÝ|ÉϺ£Í¬Ö¾ - ÉϺ£Í¬Ö¾ÁÄÌìÊÒ - ÉϺ£Í¬Ö¾½»ÓÑ
GMT+8, 2023-1-27 05:53 , Processed in 0.083005 second(s), 19 queries .
© 2001-2013 Comsenz Inc.